Uses of medication:
Darunavir is a human immunodeficiency virus (HIV-1) protease inhibitor used for the treatment of HIV-1 infection in adult and pediatric patients aged 3 years and older. Darunavir must be co-administered with ritonavir and with other antiretroviral agents.
Darunavir tablets must be co-administered with ritonavir to exert its therapeutic effect. In absence of appropriately co-administer Darunavir with ritonavir will result in the plasma levels of darunavir that will be not sufficient to achieve the required antiviral effect and will alter a few drug interactions. Patients who have difficulty swallowing Darunavir tablets can use the 100 mg per mL Darunavir oral suspension.
The recommended dose for treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance-associated substitutions is 800 mg (one 800 mg tablet) taken with ritonavir 100 mg once daily and with food.
The recommended dose for treatment-experienced adults with at least one darunavir resistance associated substitution is 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food.
The recommended dosage for pregnant patients is 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food.
Pediatric patients (aged 3 to less than 18 years and weighing at least 10 kg): a dosage of darunavir and ritonavir is based on body weight and should not exceed the adult dose. Darunavir is taken with food.
The most commonly reported side effects due to Darunavir/Ritonavir include:
- abdominal pain